FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2100080357> ?p ?o ?g. }

• W2100080357 endingPage "243" @default.
• W2100080357 startingPage "236" @default.
• W2100080357 abstract "The generation of urokinase plasminogen activator (uPA) by tumours is an important pathway for neoplastic cell invasion and metastasis. Indeed in several tumour types, elevated levels of uPA, its receptor (uPAR) or its inhibitor plasminogen activator inhibitor-1 (PAI-1) is associated with a poorer prognosis. Since endothelial cells also use this proteolytic system to remodel the extracellular matrix during angiogenesis and since angiogenesis, as assessed by microvessel density, is also a predictor of patient survival, this study was designed to investigate the relationship between angiogenesis and the urokinase system in breast tumours. The aims were to assess whether the uPA, uPAR and/or PAI-1 correlates with angiogenic activity and could therefore be a useful objective clinical measure of tumour neovascularization; and to clarify whether the poor outcome associated with high levels of the urokinase system is due to its association with angiogenesis. The study also sought to examine the relationship between the uPA system and vessel remodelling using loss of a basement membrane epitope (LH39) normally associated with established capillaries. The cytosolic levels of uPA, PAI-1 and uPAR were therefore measured by enzyme linked immunoabsorbent assay, together with tumour vascularity, in 136 well-characterized invasive breast carcinomas. There were significant relationships between uPA and uPAR (Spearman r=0.37, p<0.0001), uPA and PAI-1 (Spearman r=0.19, p=0.03) and between uPAR and PAI-1 (Spearman r=0.23 p=0.01). A significant correlation was also observed between PAI-1 and vessel remodelling (Spearman r=0.34, p=0.04), patient age (p=0.01), nodal status (p=0.047) and tumour grade (p=0.04), but no association between tumour vascularity and PAI (p=0.96), uPA (p=0.69) or uPAR (p=0.81) was present. No significant association was seen between any of the urokinase variables and expression of the angiogenic factor thymidine phosphorylase. Furthermore, no significant associations were found between any of the studied parameters and overall survival in a univariate analysis of the cancer patients. A multivariate Cox proportional hazard model of overall survival showed that uPA (p=0.15), but not uPAR (p=0.52) or PAI-1 (p=0.61), gave no additional prognostic information. These findings show that uPA may work via an independent pathway to angiogenesis and therefore combined blockade of uPA and angiogenesis may have additional therapeutic benefits. It also shows, as recently demonstrated in animal models, that PAI-1 may be a key regulator of vascular remodelling in human cancer." @default.
• W2100080357 created "2016-06-24" @default.
• W2100080357 creator A5027807165 @default.
• W2100080357 creator A5029695207 @default.
• W2100080357 creator A5071319458 @default.
• W2100080357 creator A5075048609 @default.
• W2100080357 creator A5079633934 @default.
• W2100080357 creator A5088637763 @default.
• W2100080357 date "2001-08-08" @default.
• W2100080357 modified "2023-09-27" @default.
• W2100080357 title "Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer" @default.
• W2100080357 cites W1602370661 @default.
• W2100080357 cites W1670322156 @default.
• W2100080357 cites W1955500014 @default.
• W2100080357 cites W1966719969 @default.
• W2100080357 cites W1967070952 @default.
• W2100080357 cites W1988307856 @default.
• W2100080357 cites W1988978946 @default.
• W2100080357 cites W1992165616 @default.
• W2100080357 cites W1995406904 @default.
• W2100080357 cites W2002951101 @default.
• W2100080357 cites W2005113904 @default.
• W2100080357 cites W2006860708 @default.
• W2100080357 cites W2013336992 @default.
• W2100080357 cites W2014069639 @default.
• W2100080357 cites W2026151657 @default.
• W2100080357 cites W2027833512 @default.
• W2100080357 cites W2029837224 @default.
• W2100080357 cites W2032220711 @default.
• W2100080357 cites W2032931156 @default.
• W2100080357 cites W2034350621 @default.
• W2100080357 cites W2035140916 @default.
• W2100080357 cites W2038229795 @default.
• W2100080357 cites W2043396483 @default.
• W2100080357 cites W2055218751 @default.
• W2100080357 cites W2055299311 @default.
• W2100080357 cites W2057785596 @default.
• W2100080357 cites W2057790488 @default.
• W2100080357 cites W2073604224 @default.
• W2100080357 cites W2079459026 @default.
• W2100080357 cites W2083500716 @default.
• W2100080357 cites W2085328261 @default.
• W2100080357 cites W2095181507 @default.
• W2100080357 cites W2100428167 @default.
• W2100080357 cites W2102121261 @default.
• W2100080357 cites W2102577298 @default.
• W2100080357 cites W2112871946 @default.
• W2100080357 cites W2127472491 @default.
• W2100080357 cites W2131420129 @default.
• W2100080357 cites W2134562408 @default.
• W2100080357 cites W2158095199 @default.
• W2100080357 cites W2158743409 @default.
• W2100080357 cites W2200649958 @default.
• W2100080357 cites W2300710538 @default.
• W2100080357 cites W23122061 @default.
• W2100080357 cites W2323421875 @default.
• W2100080357 doi "https://doi.org/10.1002/path.931" @default.
• W2100080357 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11592104" @default.
• W2100080357 hasPublicationYear "2001" @default.
• W2100080357 type Work @default.
• W2100080357 sameAs 2100080357 @default.
• W2100080357 citedByCount "47" @default.
• W2100080357 countsByYear W21000803572012 @default.
• W2100080357 countsByYear W21000803572015 @default.
• W2100080357 countsByYear W21000803572016 @default.
• W2100080357 countsByYear W21000803572018 @default.
• W2100080357 countsByYear W21000803572019 @default.
• W2100080357 countsByYear W21000803572022 @default.
• W2100080357 crossrefType "journal-article" @default.
• W2100080357 hasAuthorship W2100080357A5027807165 @default.
• W2100080357 hasAuthorship W2100080357A5029695207 @default.
• W2100080357 hasAuthorship W2100080357A5071319458 @default.
• W2100080357 hasAuthorship W2100080357A5075048609 @default.
• W2100080357 hasAuthorship W2100080357A5079633934 @default.
• W2100080357 hasAuthorship W2100080357A5088637763 @default.
• W2100080357 hasConcept C121608353 @default.
• W2100080357 hasConcept C126322002 @default.
• W2100080357 hasConcept C134018914 @default.
• W2100080357 hasConcept C142724271 @default.
• W2100080357 hasConcept C2776892390 @default.
• W2100080357 hasConcept C2778271429 @default.
• W2100080357 hasConcept C2779013556 @default.
• W2100080357 hasConcept C2779679481 @default.
• W2100080357 hasConcept C2780394083 @default.
• W2100080357 hasConcept C2780675426 @default.
• W2100080357 hasConcept C502942594 @default.
• W2100080357 hasConcept C530470458 @default.
• W2100080357 hasConcept C56219504 @default.
• W2100080357 hasConcept C71924100 @default.
• W2100080357 hasConcept C86803240 @default.
• W2100080357 hasConceptScore W2100080357C121608353 @default.
• W2100080357 hasConceptScore W2100080357C126322002 @default.
• W2100080357 hasConceptScore W2100080357C134018914 @default.
• W2100080357 hasConceptScore W2100080357C142724271 @default.
• W2100080357 hasConceptScore W2100080357C2776892390 @default.
• W2100080357 hasConceptScore W2100080357C2778271429 @default.
• W2100080357 hasConceptScore W2100080357C2779013556 @default.
• W2100080357 hasConceptScore W2100080357C2779679481 @default.

• next